ThinkstockIllumina Inc. (NASDAQ: ILMN) reported its earnings before the market opened Monday as $0.77 in earnings per share and $481 in revenue which beat out consensus estimates. On the heels of this earnings report,…
Connecture Inc. has filed with the Securities and Exchange Commission to have an initial public offering.
Goldman Sachs has initiated on MannKind with a Neutral rating and a $6 price target, a move that may seem to some as the equivalent to a downgrade.
Some of the Ebola high-flying stocks saw their share prices crater on Monday as Ebola fears are subsiding for several reasons.
NewLink Genetics announced that it has entered into an exclusive worldwide license agreement with Genentech for the development of NewLink's IDO pathway inhibitor.
A new report from Merrill Lynch highlights five biotechs that have been absolutely crushed but have outstanding potential and catalysts that can drive them much higher.
Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brought a mixed view for this group.
Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears.
In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy right now.
Johnson & Johnson reported better-than-expected third-quarter 2014 results before markets opened Tuesday.
Fears of Ebola have plagued the United States since late September, and some biotech companies have capitalized on this fear.
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Diplomat Pharmacy priced its IPO shares at $13 on Thursday, but when the stock began trading Friday morning it opened at $16.
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Lakeland Industries shares have skyrocketed since the beginning of October as investors take a pessimistic view on recent Ebola news.